MITIGATE

Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with metastatic Gastrointestinal Stromal Tumours

Coordinatore	RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG    more  Organization address address: SEMINARSTRASSE 2 city: HEIDELBERG postcode: 69117 contact info Titolo: Mrs. Nome: Melanie Cognome: Stein Email: send email Telefono: +49 621 383 5575
Nazionalità Coordinatore	Germany [DE]
Totale costo	5˙848˙215 €
EC contributo	4˙494˙253 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2017-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG  Organization address address: SEMINARSTRASSE 2 city: HEIDELBERG postcode: 69117 contact info Titolo: Mrs. Nome: Melanie Cognome: Stein Email: send email Telefono: +49 621 383 5575	DE (HEIDELBERG)	coordinator	1˙553˙768.00
2	EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG  Organization address address: Neutorgasse 9/2 city: VIENNA postcode: 1010 contact info Titolo: Dr. Nome: Pamela Cognome: Zolda Email: send email Telefono: +43 15334064538 Fax: +43 15357041	AT (VIENNA)	participant	464˙000.00
3	Advanced Accelerator Applications  Organization address address: Rue Diesel 20 city: Saint Genis Pouilly postcode: 1630 contact info Titolo: Dr. Nome: Jean Philippe Cognome: Meunier Email: send email Telefono: +33 4 50993070 Fax: +33 4 50993071	FR (Saint Genis Pouilly)	participant	449˙640.00
4	FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V  Organization address address: Hansastrasse 27C city: MUENCHEN postcode: 80686 contact info Titolo: Mr. Nome: Walter Cognome: Krause Email: send email Telefono: +49 89 12052713 Fax: +49 89 12057534	DE (MUENCHEN)	participant	405˙422.00
5	MEDIZINISCHE UNIVERSITAET INNSBRUCK  Organization address address: Christoph-Probst Platz 1 city: INNSBRUCK postcode: 6020 contact info Titolo: Prof. Nome: Werner Cognome: Jaschke Email: send email Telefono: +43 512 504 22761 Fax: +43 512 504 22758	AT (INNSBRUCK)	participant	341˙400.00
6	RAPID BIOMEDIZINISCHE GERATE RAPID BIOMEDICAL GMBH  Organization address address: KETTELERSTRASSE 3-11 PAV 2-4 city: RIMPAR postcode: 97222 contact info Titolo: Mr. Nome: Kay Cognome: Lipinski Email: send email Telefono: +49 9365 8826 32 Fax: +49 9365 8826 99	DE (RIMPAR)	participant	329˙488.00
7	STEMCELL TECHNOLOGIES SARL  Organization address address: MINIPAR POLYTEC RUE DES BERGES 40 city: GRENOBLE postcode: 38000 contact info Titolo: Mrs. Nome: Marie-Claude Cognome: Genevay Email: send email Telefono: +33 476047530 Fax: +33 476189963	FR (GRENOBLE)	participant	312˙320.00
8	CAGE CHEMICALS SRL  Organization address address: VIA BOVIO 6 city: NOVARA postcode: 28100 contact info Titolo: Dr. Nome: Camilla Cognome: Cavallotti Email: send email Telefono: 393212000000	IT (NOVARA)	participant	307˙795.00
9	HOCHSCHULE MANNHEIM  Organization address address: WINDECKSTRASSE 110 city: MANNHEIM postcode: 68163 contact info Titolo: Mr. Nome: Winfried Cognome: Hugo Email: send email Telefono: 496213000000	DE (MANNHEIM)	participant	229˙500.00
10	UNIVERSITA DEGLI STUDI DI TORINO  Organization address address: Via Giuseppe Verdi 8 city: TORINO postcode: 10124 contact info Titolo: Prof. Nome: Giorgio Cognome: Inghirami Email: send email Telefono: 390116000000 Fax: +39 01 16334623	IT (TORINO)	participant	100˙920.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

Gastrointestinal stromal tumours (GIST) are a rare disease that metastasises in up to 85% of patients with subsequent median progression-free survival (PFS) of only around 30 months. Tumours are characterised by activating mutations in the KIT or the PDGFRA gene and therefore treatment is mainly based on tyrosine kinase inhibitors designed to block these mutated receptors. However, drug resistance is often based on mutations changing the conformity of the receptor, leaving little effective therapeutic options to these patients. To date, second line chemotherapy offers a median PFS of 6-9 months and external beam radiotherapy is limited by organs at risk close to the tumour. Alternative approaches such as endoradiotherapy or minimally-invasive ablation techniques are effective for local control but are inconsistently used and are not tailored to the individual patient's type of disease. To address these issues, we propose a closed-loop personalised treatment concept combining endoscopic-assisted tissue sampling, inline biotechnology and targeted molecular PET imaging probe development combined with minimally-invasive treatment monitored by new functional and metabolic MR imaging techniques. A consistent value chain across European academic centres, research institutes and SMEs will be established for mass spectrometry of tumours, linkage of radiochemical molecular imaging probes, design of new immunocompromised animal models and targeted therapeutic radiopharmaceuticals. This closed-loop platform will minimise fragmentation of treatment approaches by a coherent molecular-based multimodality concept, thus providing new treatment options. On a larger scale, the MITIGATE platform can be expanded to further patient cohorts with oligometastatic diseases such as other sarcomas or renal cell carcinoma. For SMEs the access to new animal models and ligands along with translation into clinical practice will strengthen their market share for new probes and imaging technology.